Thus, while the percentage of ICOS+ CD8+ T cells was significantly higher in the periphery with combination treatment, the responses observed in the tumor were similar in MVA-BN-HER-2-treated groups irrespective of anti-CTLA-4 treatment. This evidence concerns the gene ERBB2 and neoplasm.